Mizuho upgraded shares of Eikon Therapeutics (NASDAQ:EIKN – Free Report) to a strong-buy rating in a research note issued to investors on Wednesday,Zacks reports.
Several other equities analysts have also recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Eikon Therapeutics in a research note on Friday, August 21st. Wedbush decreased their price objective on shares of Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating for the company in a report on Friday, August 14th. Finally, Weiss Ratings upgraded shares of Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Eikon Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $25.00.
Read Our Latest Research Report on EIKN
Eikon Therapeutics Stock Performance
Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.63) EPS for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.02). Equities research analysts predict that Eikon Therapeutics will post -7.24 earnings per share for the current fiscal year.
Insider Buying and Selling at Eikon Therapeutics
In other news, major shareholder Group Iv Gp Lp Column bought 89,200 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was acquired at an average price of $11.56 per share, with a total value of $1,031,152.00. Following the completion of the purchase, the insider directly owned 89,200 shares of the company’s stock, valued at $1,031,152. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. BlackRock Inc. lifted its holdings in Eikon Therapeutics by 29.0% in the 2nd quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock valued at $55,873,000 after acquiring an additional 962,046 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new position in shares of Eikon Therapeutics in the 2nd quarter worth approximately $3,341,000. Comprehensive Financial Management LLC bought a new stake in shares of Eikon Therapeutics in the 2nd quarter worth approximately $1,517,000. The Manufacturers Life Insurance Company acquired a new stake in Eikon Therapeutics during the second quarter valued at approximately $461,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in Eikon Therapeutics during the second quarter valued at approximately $142,000.
About Eikon Therapeutics
Eikon Therapeutics, Inc is a biotechnology company focused on discovering and developing medicines by combining advanced live-cell imaging with drug discovery and development. The company’s platform is designed to track individual molecules and cellular processes in real time, providing researchers with detailed insight into how potential therapies work inside living cells.
Eikon applies this technology primarily to the development of treatments for serious diseases, including cancer and other conditions involving complex biological pathways.
Read More
- Five stocks we like better than Eikon Therapeutics
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Eikon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eikon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
